NASDAQ:AKCA - Akcea Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$23.29 -0.31 (-1.31 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$23.29
Today's Range$22.5886 - $23.82
52-Week Range$8.10 - $33.99
Volume203,815 shs
Average Volume363,351 shs
Market Capitalization$1.93 billion
P/E Ratio-10.40
Dividend YieldN/A
BetaN/A

About Akcea Therapeutics (NASDAQ:AKCA)

Akcea Therapeutics logoAkcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease due to elevated triglyceride levels. It has strategic collaboration with Novartis Pharma AG. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.

Receive AKCA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKCA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKCA
CUSIPN/A
Phone617-207-0202

Debt

Debt-to-Equity RatioN/A
Current Ratio2.55
Quick Ratio2.55

Price-To-Earnings

Trailing P/E Ratio-10.40
Forward P/E Ratio-12.80
P/E GrowthN/A

Sales & Book Value

Annual Sales$55.21 million
Price / Sales36.11
Cash FlowN/A
Price / CashN/A
Book Value$1.71 per share
Price / Book13.62

Profitability

EPS (Most Recent Fiscal Year)($2.24)
Net Income$-109,750,000.00
Net Margins-126.00%
Return on Equity-75.90%
Return on Assets-27.67%

Miscellaneous

Employees100
Outstanding Shares85,590,000

Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions

What is Akcea Therapeutics' stock symbol?

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

How were Akcea Therapeutics' earnings last quarter?

Akcea Therapeutics (NASDAQ:AKCA) posted its quarterly earnings data on Thursday, May, 3rd. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.07. The company earned $17.11 million during the quarter, compared to analyst estimates of $12.12 million. Akcea Therapeutics had a negative return on equity of 75.90% and a negative net margin of 126.00%. The firm's quarterly revenue was up 181.0% compared to the same quarter last year. View Akcea Therapeutics' Earnings History.

What price target have analysts set for AKCA?

4 brokerages have issued 12 month target prices for Akcea Therapeutics' shares. Their predictions range from $20.00 to $38.00. On average, they expect Akcea Therapeutics' share price to reach $29.3333 in the next twelve months. View Analyst Ratings for Akcea Therapeutics.

Who are some of Akcea Therapeutics' key competitors?

Who are Akcea Therapeutics' key executives?

Akcea Therapeutics' management team includes the folowing people:
  • Ms. Paula Soteropoulos, CEO, Pres & Director (Age 50)
  • Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 45)
  • Dr. Louis St. Laurence O'Dea MB, BCh, BAO, FRCP(C), Chief Medical Officer, Exec. VP & Head of Regulatory Affairs (Age 67)
  • Mr. Michael F. MacLean, Chief Financial Officer (Age 52)
  • D. Wade Walke Ph.D., VP of Corp. Communications & Investor Relations

When did Akcea Therapeutics IPO?

(AKCA) raised $125 million in an IPO on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager.

Has Akcea Therapeutics been receiving favorable news coverage?

News articles about AKCA stock have been trending positive recently, according to Accern Sentiment. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Akcea Therapeutics earned a news sentiment score of 0.36 on Accern's scale. They also assigned news headlines about the company an impact score of 47.59 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Akcea Therapeutics' major shareholders?

Akcea Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include IONIS PHARMACEUTICALS INC (75.00%), BB Biotech AG (3.58%), BlackRock Inc. (2.66%), Altrinsic Global Advisors LLC (0.22%), Eventide Asset Management LLC (0.20%) and Northern Trust Corp (0.26%). View Institutional Ownership Trends for Akcea Therapeutics.

Which institutional investors are selling Akcea Therapeutics stock?

AKCA stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, BlackRock Inc., New York State Common Retirement Fund, Wells Fargo & Company MN, MetLife Investment Advisors LLC, JPMorgan Chase & Co. and Zurcher Kantonalbank Zurich Cantonalbank. View Insider Buying and Selling for Akcea Therapeutics.

Which institutional investors are buying Akcea Therapeutics stock?

AKCA stock was purchased by a variety of institutional investors in the last quarter, including BB Biotech AG, Bellevue Group AG, Altrinsic Global Advisors LLC, Jane Street Group LLC, Millennium Management LLC, Barclays PLC, Schwab Charles Investment Management Inc. and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Akcea Therapeutics.

How do I buy shares of Akcea Therapeutics?

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akcea Therapeutics' stock price today?

One share of AKCA stock can currently be purchased for approximately $23.29.

How big of a company is Akcea Therapeutics?

Akcea Therapeutics has a market capitalization of $1.93 billion and generates $55.21 million in revenue each year. The company earns $-109,750,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis. Akcea Therapeutics employs 100 workers across the globe.

How can I contact Akcea Therapeutics?

Akcea Therapeutics' mailing address is 55 CAMBRIDGE PARKWAY SUITE 100, CAMBRIDGE MA, 92010. The company can be reached via phone at 617-207-0202 or via email at [email protected]


MarketBeat Community Rating for Akcea Therapeutics (AKCA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  249
MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe AKCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Akcea Therapeutics (NASDAQ:AKCA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Akcea Therapeutics in the last 12 months. Their average twelve-month price target is $29.3333, suggesting that the stock has a possible upside of 25.95%. The high price target for AKCA is $38.00 and the low price target for AKCA is $20.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.503.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.3333$26.6667$24.00$24.00
Price Target Upside: 25.95% upside14.56% downside44.49% upside44.49% upside

Akcea Therapeutics (NASDAQ:AKCA) Consensus Price Target History

Price Target History for Akcea Therapeutics (NASDAQ:AKCA)

Akcea Therapeutics (NASDAQ:AKCA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2018Wells Fargo & CoUpgradeMarket Perform ➝ OutperformHighView Rating Details
5/4/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$42.00 ➝ $38.00N/AView Rating Details
3/16/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$20.00 ➝ $30.00HighView Rating Details
2/27/2018CowenDowngradeOutperform ➝ Market PerformHighView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Akcea Therapeutics (NASDAQ:AKCA) Earnings History and Estimates Chart

Earnings by Quarter for Akcea Therapeutics (NASDAQ:AKCA)

Akcea Therapeutics (NASDAQ:AKCA) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.82 EPS
Next Year EPS Consensus Estimate: $1.41 EPS

Akcea Therapeutics (NASDAQ AKCA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018Q1 2018($0.37)($0.44)$12.12 million$17.11 millionViewN/AView Earnings Details
2/26/2018Q4 2017($0.23)($0.26)$15.48 million$18.04 millionViewN/AView Earnings Details
11/6/2017Q3 2017($0.21)($0.18)$15.48 million$13.45 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.27)$14.13 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Akcea Therapeutics (NASDAQ:AKCA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Akcea Therapeutics (NASDAQ AKCA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.88%
Institutional Ownership Percentage: 23.96%
Insider Trading History for Akcea Therapeutics (NASDAQ:AKCA)
Institutional Ownership by Quarter for Akcea Therapeutics (NASDAQ:AKCA)

Akcea Therapeutics (NASDAQ AKCA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/17/2018Ionis Pharmaceuticals IncMajor ShareholderBuy10,666,666$18.75$199,999,987.5053,447,879View SEC Filing  
7/19/2017Ionis Pharmaceuticals IncMajor ShareholderBuy3,125,000$8.00$25,000,000.0028,884,540View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Akcea Therapeutics (NASDAQ AKCA) News Headlines

Source:
DateHeadline
Wired News – FDA’s Advisory Committee Supports Approval of Akcea’s WAYLIVRA(TM) for Treatment of Familial Chylomicronemia SyndromeWired News – FDA’s Advisory Committee Supports Approval of Akcea’s WAYLIVRA(TM) for Treatment of Familial Chylomicronemia Syndrome
finance.yahoo.com - May 15 at 10:00 AM
Akcea Therapeutics (AKCA) Lifted to Outperform at Wells FargoAkcea Therapeutics (AKCA) Lifted to Outperform at Wells Fargo
www.americanbankingnews.com - May 11 at 6:33 PM
FDA Ad Com renders split vote on Akceas volanesorsenFDA Ad Com renders split vote on Akcea's volanesorsen
seekingalpha.com - May 11 at 4:28 PM
Akcea Gets Green Light From FDA, Shares ClimbAkcea Gets Green Light From FDA, Shares Climb
www.baystreet.ca - May 11 at 4:28 PM
Why Akcea Therapeutics Rocketed Higher TodayWhy Akcea Therapeutics Rocketed Higher Today
www.fool.com - May 11 at 1:16 PM
Wells Fargo Upgrades Akcea Therapeutics, Inc. (AKCA) to OutperformWells Fargo Upgrades Akcea Therapeutics, Inc. (AKCA) to Outperform
www.streetinsider.com - May 11 at 10:26 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akcea Therapeutics, Inc. (AKCA)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akcea Therapeutics, Inc. (AKCA)
finance.yahoo.com - May 10 at 4:35 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Akcea Therapeutics, Inc. - AKCASHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Akcea Therapeutics, Inc. - AKCA
finance.yahoo.com - May 10 at 4:35 PM
BidaskClub Downgrades Akcea Therapeutics (AKCA) to HoldBidaskClub Downgrades Akcea Therapeutics (AKCA) to Hold
www.americanbankingnews.com - May 10 at 11:01 AM
Akcea Therapeutics (AKCA) Lowered to "Hold" at Zacks Investment ResearchAkcea Therapeutics (AKCA) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 9 at 5:09 PM
Ionis Pharmaceuticals Prepares for LaunchIonis Pharmaceuticals Prepares for Launch
finance.yahoo.com - May 9 at 4:30 PM
Are Options Traders Betting on a Big Move in Akcea Therapeutics (AKCA) Stock?Are Options Traders Betting on a Big Move in Akcea Therapeutics (AKCA) Stock?
finance.yahoo.com - May 9 at 9:32 AM
Stock Traders Buy High Volume of Put Options on Akcea Therapeutics (AKCA)Stock Traders Buy High Volume of Put Options on Akcea Therapeutics (AKCA)
www.americanbankingnews.com - May 9 at 6:38 AM
FDA Ad Com Thursday for Akceas volanesorenFDA Ad Com Thursday for Akcea's volanesoren
seekingalpha.com - May 8 at 9:24 AM
Akcea Therapeutics (AKCA) CEO Paula Soteropoulos on Q1 2018 Results - Earnings Call TranscriptAkcea Therapeutics' (AKCA) CEO Paula Soteropoulos on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 4:25 PM
BRIEF-Akcea Therapeutics Q1 Loss Per Share $0.44BRIEF-Akcea Therapeutics Q1 Loss Per Share $0.44
www.reuters.com - May 5 at 9:48 AM
BidaskClub Lowers Akcea Therapeutics (AKCA) to BuyBidaskClub Lowers Akcea Therapeutics (AKCA) to Buy
www.americanbankingnews.com - May 5 at 1:07 AM
Akcea Therapeutics (AKCA) Given New $38.00 Price Target at BMO Capital MarketsAkcea Therapeutics (AKCA) Given New $38.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - May 4 at 5:25 PM
FDA extends action date for Akceas inotersen to October 6; shares down 6% premarketFDA extends action date for Akcea's inotersen to October 6; shares down 6% premarket
seekingalpha.com - May 4 at 4:24 PM
Akcea Therapeutics: 1Q Earnings SnapshotAkcea Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 9:24 AM
Akcea Therapeutics (AKCA) Receives Average Recommendation of "Buy" from BrokeragesAkcea Therapeutics (AKCA) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 4 at 1:34 AM
Akcea Therapeutics (AKCA) Upgraded at ValuEngineAkcea Therapeutics (AKCA) Upgraded at ValuEngine
www.americanbankingnews.com - May 4 at 12:55 AM
Akcea Therapeutics (AKCA) Announces Quarterly  Earnings ResultsAkcea Therapeutics (AKCA) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 3 at 9:05 PM
Akcea Reports Financial Results and Highlights for First Quarter 2018Akcea Reports Financial Results and Highlights for First Quarter 2018
finance.yahoo.com - May 3 at 4:23 PM
Akcea Therapeutics (AKCA) to Release Earnings on ThursdayAkcea Therapeutics (AKCA) to Release Earnings on Thursday
www.americanbankingnews.com - May 2 at 8:10 PM
Akcea Announces Expansion of Global Early Access Program to Provide Volanesorsen to People Living with FCSAkcea Announces Expansion of Global Early Access Program to Provide Volanesorsen to People Living with FCS
finance.yahoo.com - May 2 at 9:26 AM
Akcea Therapeutics (AKCA) Rating Increased to Buy at Zacks Investment ResearchAkcea Therapeutics (AKCA) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 1 at 6:06 PM
Akcea Therapeutics Announces Presentations on Volanesorsen and FCS at the National Lipid Association Scientific SessionsAkcea Therapeutics Announces Presentations on Volanesorsen and FCS at the National Lipid Association Scientific Sessions
finance.yahoo.com - April 26 at 4:27 PM
Akcea Therapeutics to Hold First Quarter 2018 Financial Results WebcastAkcea Therapeutics to Hold First Quarter 2018 Financial Results Webcast
feeds.benzinga.com - April 26 at 7:57 AM
Akcea Therapeutics (AKCA) Upgraded by BidaskClub to "Strong-Buy"Akcea Therapeutics (AKCA) Upgraded by BidaskClub to "Strong-Buy"
www.americanbankingnews.com - April 24 at 11:02 AM
Two oral presentations further demonstrate inotersen’s impact on efficacy and safety and on patient quality of lifeTwo oral presentations further demonstrate inotersen’s impact on efficacy and safety and on patient quality of life
globenewswire.com - April 21 at 4:29 PM
Akcea up 10% on Ionis investment of $200MAkcea up 10% on Ionis investment of $200M
seekingalpha.com - April 20 at 4:29 PM
Akcea Therapeutics (AKCA) Major Shareholder Ionis Pharmaceuticals Inc Purchases 10,666,666 SharesAkcea Therapeutics (AKCA) Major Shareholder Ionis Pharmaceuticals Inc Purchases 10,666,666 Shares
www.americanbankingnews.com - April 19 at 7:18 PM
Akcea Therapeutics, Inc.: Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTRAkcea Therapeutics, Inc.: Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR
www.finanznachrichten.de - April 17 at 9:50 AM
Sarah Boyce Joins Akcea Therapeutics as President and Member of the Board of DirectorsSarah Boyce Joins Akcea Therapeutics as President and Member of the Board of Directors
finance.yahoo.com - April 17 at 9:50 AM
Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTRAkcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR
finance.yahoo.com - April 17 at 9:50 AM
Akcea Therapeutics (AKCA) Receives New Coverage from Analysts at Wells FargoAkcea Therapeutics (AKCA) Receives New Coverage from Analysts at Wells Fargo
www.americanbankingnews.com - April 12 at 9:00 PM
Akcea Therapeutics (AKCA) Research Coverage Started at Stifel NicolausAkcea Therapeutics (AKCA) Research Coverage Started at Stifel Nicolaus
www.americanbankingnews.com - April 12 at 9:00 PM
Akcea Therapeutics (AKCA) Now Covered by CowenAkcea Therapeutics (AKCA) Now Covered by Cowen
www.americanbankingnews.com - April 12 at 9:00 PM
Akcea Therapeutics (AKCA) Receives Consensus Recommendation of "Buy" from AnalystsAkcea Therapeutics (AKCA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 9 at 1:43 AM
Akcea Therapeutics (AKCA) Stock Rating Lowered by BidaskClubAkcea Therapeutics (AKCA) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 6 at 11:51 AM
How Worried Should Alnylam and Ionis Really Be About Pfizers New Data?How Worried Should Alnylam and Ionis Really Be About Pfizer's New Data?
finance.yahoo.com - April 3 at 4:29 PM
Akcea Therapeutics (AKCA) Stock Rating Reaffirmed by Stifel NicolausAkcea Therapeutics (AKCA) Stock Rating Reaffirmed by Stifel Nicolaus
www.americanbankingnews.com - April 1 at 4:16 PM
Akcea Therapeutics (AKCA) Upgraded to "Buy" by BidaskClubAkcea Therapeutics (AKCA) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - March 26 at 9:57 AM
Akcea Therapeutics (AKCA) Stock Rating Lowered by Wells FargoAkcea Therapeutics (AKCA) Stock Rating Lowered by Wells Fargo
www.americanbankingnews.com - March 24 at 10:39 PM
Akcea Therapeutics (AKCA) Cut to Hold at Stifel NicolausAkcea Therapeutics (AKCA) Cut to Hold at Stifel Nicolaus
www.americanbankingnews.com - March 24 at 10:02 PM
Cowen Lowers Akcea Therapeutics (AKCA) to Market PerformCowen Lowers Akcea Therapeutics (AKCA) to Market Perform
www.americanbankingnews.com - March 24 at 10:02 PM
BMO Capital Markets Boosts Akcea Therapeutics (AKCA) Price Target to $30.00BMO Capital Markets Boosts Akcea Therapeutics (AKCA) Price Target to $30.00
www.americanbankingnews.com - March 24 at 9:28 PM
Akcea Therapeutics (AKCA) Upgraded at BidaskClubAkcea Therapeutics (AKCA) Upgraded at BidaskClub
www.americanbankingnews.com - March 24 at 1:37 PM
Akcea Therapeutics (AKCA) Upgraded to Strong-Buy at BidaskClubAkcea Therapeutics (AKCA) Upgraded to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 23 at 9:00 PM

SEC Filings

Akcea Therapeutics (NASDAQ:AKCA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Akcea Therapeutics (NASDAQ:AKCA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Akcea Therapeutics (NASDAQ AKCA) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.